Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 133ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
0
4
0
3
1
2
0
1
0
Sinônimo Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Aplicação A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
Numero VAT: 75330-75-5
Privada: ≥97%
Peso Molecular: 404.54
Separar por Funcao: C24H36O5
* Refere-se a Certificado de Análise para data especifica de lotes (incluindo-se o conteúdo de agua).
Faça a sua avaliação desse produto e receba 15 CruzCredits

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


Referencias

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

Estado físico :
Solid
Derivado de :
Non-native source; synthetic
envie :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
Manutencao :
Store at -20° C
Ponto de fusão :
175.4° C
Ponto de fervura :
~559.2° C at 760 mmHg (Predicted)
Densidade :
~1.1 g/cm3 (Predicted)
Indice de produtos :
n20D 1.53
Reatividade :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Data ki :
HMG-CoA reductase: Ki= 0.6 nM
Para uso em exclusivo em pesquisa. Não se destina a uso em diagnostico e tratamento.
WGK Alemanha :
3
RTECS :
EK7907000
PubChem CID :
53232
Indice de produtos :
14: 5586
Numero de FAX :
MFCD00072164

Baixar SDS (MSDS)

Certificado de Análise

É necessário o Adobe Acrobat Reader para visualizar corretamente,
imprimir e comentar os documentos PDF

Lovastatin  Citacoes dos Produtos

Visualizar com outras pessoas usaram Lovastatin. Clique em PubMed para ver .

Citações 1 para 7 de 7 total

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

Citações 1 para 7 de 7 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 153ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 48ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

A Santa Cruz Biotecnologia, Inc. é a líder mundial no desenvolvimento de produtos para o mercado de pesquisa biomédica. Ligue para nós ligação gratuita 1-800-457-3801..
Direito de Reprodução© 2007-2020 Santa Cruz Biotechnology, Inc. Todos os direitos reservados. "Santa Cruz Biotechnology", Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", "EZ Touch" são marcas registradas da Santa Cruz Biotechnology, Inc. Todas as marcas registradas são propriedade dos seus respectivos donos.